VistaGen Therapeutics Inc

VistaGen Therapeutics Inc a clinicalstage biopharmaceutical company engages in developing and commercializing various medicines with the potential to care for anxiety depression and other disorders of the central nervous system CNS The companys CNS pipeline includes PH94B a rapidonset neuroactive nasal spray which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder Its PH94B product candidature also has potential to treat a range of anxiety disorders including adjustment disorder with anxiety postpartum anxiety posttraumatic stress disorder preprocedural anxiety and panic disorders The companys CNS pipeline also comprises PH10 a rapidonset neuroactive nasal spray which is in preparation for Phase 2B clinical development as a standalone treatment for major depressive disorder MDD and AV101 an oral NmethylDaspartate receptor antagonist which is in development in combination with oral probenecid as a potential treatment of levodopainduced dyskinesia MDD neuropathic pain and suicidal ideation It has contract research and development agreement with Cato Research Ltd license agreement with Pherin Pharmaceuticals Inc and license and collaboration agreement with EverInsight Therapeutics Inc VistaGen Therapeutics Inc was founded in 1998 and is headquartered in South San Francisco California